酒精性肝病治疗进展*

doi:10.3969/j.issn.1672-5069.2014.01.029

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (1): 89-91.doi: 10.3969/j.issn.1672-5069.2014.01.029

酒精性肝病治疗进展^*

徐亮综述, 宓余强审校

300192 天津市第二人民医院天津市肝病医学研究所/中西医结合二科

收稿日期:2013-10-17 出版日期:2014-02-28 发布日期:2016-04-11
通讯作者: 宓余强,E-mail：yuqiangmi68@163.com
作者简介:徐亮,男,33岁,医学硕士,主治医师。主要从事脂肪性肝病和病毒性肝病的临床与基础研究。E-mail：xuyangliang2004@sina.com
基金资助:
天津市卫生局科技处基金（编号：09KZ10/12KG119）

Progress in treatment of alcoholic liver disease

Xu Liang, Mi Yuqiang

Institute of Liver Diseases,Second People’s Hospital,Tianjing 300192

Received:2013-10-17 Online:2014-02-28 Published:2016-04-11

摘要/Abstract

摘要： 酒精性肝病是影响人们健康的常见肝病之一。积极预防、合理治疗可以有效地控制病情进展。过量酒精摄入是导致人体疾患的主要原因,重症酒精性肝病的治疗为该病治疗的重点和热点。Child-Pugh分级、Maddrey判别函数、MELD模型、GAHS评分、年龄-胆红素-INR-肌酐（ABIC）评分及Lille评分可较好地预测预后,评判疗效。肝移植仍为终末期酒精性肝病的主要治疗手段。

关键词: 酒精性肝病, 肝功能评价模型, 糖皮质激素, 治疗

Abstract: Alcoholic liver disease（ALD） is one of the most common liver diseases. The treatment of severe alcoholic hepatitis（SAH）and the control of alcohol abuse are the hot spots in this field. Child-Pugh class,Maddrey discriminate function,the model of end-stage liver disease（MELD）,Glasgow alcoholic hepatitis score,age/bilirubin/INR/creatinine（ABIC）score,and Lille score systems can be used to predict the prognosis of patients with SAH. Liver transplantation is still the major treatment for patients with ALD at end-stage illness.

Key words: Alcoholic liver disease, Independent predictor, Glucocorticoids, Therapy

徐亮综述, 宓余强审校. 酒精性肝病治疗进展^*[J]. 实用肝脏病杂志, 2014, 17(1): 89-91.

Xu Liang, Mi Yuqiang. Progress in treatment of alcoholic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 89-91.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志,2010,18（3）：167-170.
[2] 鲁晓岚,陶明,罗金燕,等. 饮酒与肝病流行病学调查. 中华肝脏病杂志,2002,10：467-468.
[3] 黄顺玲,戴水奇,张雪红,等. 湖南省酒精性肝病流行病学调查概况. 中国医师杂志,2005,7：426-427.
[4] 厉有名. 酒精性肝病的流行病学特点.实用肝脏病杂志,2012,15（3）：180-182.
[5] European Association for the Study of the Liver. EASL clinical practical guidelines;management of alcoholic liver disease. J Hepatol,2012,57（2）：399-420.
[6] Phillips M,Curtis H,Portmann B,et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis a randomised clinical trial. J Hepatol,2006,44：784-790.
[7] Philippe M,John O,Robert LC,et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis： meta-analysis of individual patient data. Gut,2011,60：2 255-260.
[8] Pessione F,Ramond MJ,Peters L,et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis,smoking and abstinence. Liver Int,2003,23：45-53.
[9] 买买提江·吾布力·艾山,孙福荣,王炳元. 酒精性肝炎的防治进展. 胃肠病学与肝脏病学,2013,22（3）：208-209.
[10] Stickel F,Hoehn B,Schuppan D,et al. Review article：nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther,2003,18：357-373.
[11] Hpilenya LS,Muzychenko AP,Oasbarrini G,et a1. Metadoxine in acute alcohol intoxication：a double-blind,randomized,placebo-controlled study. Alcohol Clin Exp Res,2002,26：340-346.
[12] Fiellin DA,O’Connor PG,Holmboe ES,et al. Risk for delirium tremens in patients with alcohol withdrawal syndrome. Subst Abuse,2002,23：83-94.
[13] Amato L,Minozzi S,Vecchi S,et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev,2010,3：CD005063.
[14] Mayo-Smith MF,Beecher LH,Fischer TL,et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med,2004,164：1405-1412.
[15] Lucey M,Mathurin P,Morgan TR. Alcoholic hepatitis. N Engl J Med,2009,360：2758-2769.
[16] Louvet A,Wartel F,Castel H,et al. Prospective screening of infection in patients with severe alcoholic hepatitis treated with steroids：early response to therapy is the key factor. Gastroenterology,2009,137：541-548.
[17] Matlnain P,Abdelnour M,Ramond MJ,et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.Hepatologly,2003, 38：1363-1369.
[18] 王菲,王炳元.糖皮质激素在重症酒精性肝炎治疗中的应用. 中华肝脏病杂志,2011,19（8）：630-633.
[19] 刘畅,王颖,王炳元,等. 88例酒精性肝炎临床特征及疗效分析.药品评价,2007,4：110-113.
[20] Louver A,Naveau S,Abdelnour M,et al. The Lille model： a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology,2007,45： 1348-1354.
[21] Akriviadis E,Botla R,Briggs W,et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis：a double-blind,placebo-controlled trial. Gastroenterology,2000,119：1637-1648.
[22] Mathurin P,Louvet A,Dao T,et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival：results of the Corpentox trial. Hepatology,2011,54：391A.
[23] Nguyen-Khac E,Thevenot T,Piquet MA,et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med, 2011,365：1781-1789.
[24] Moreno C,Langlet P,Hittelet A,et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis：a randomized multicenter controlled trial. J Hepatol,2010,53：1117-1122.
[25] Mandal P,Pritchard MT,Nagy LE. Anti-inflammmatory pathways and alcoholic liver disease：role of an adiponectin/interleukin-10/home oxygenase-1 pathway. World J Gastroenterol,2010,16：1330-1336.

酒精性肝病治疗进展^*

Progress in treatment of alcoholic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[9]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[10]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[11]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[12]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[13]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.